ZYBERNO
Stock Report
Updated Sep 1, 2026

REVELATION BIOSCIENCES, INC. (REVB)

Healthcare • NASDAQ

$0.99

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
REVELATION BIOSCIENCES, INC. (REVB) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-100.2%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.09x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-832.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

REVELATION BIOSCIENCES, INC. (REVB) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.99
Market Cap:$3.79M

Valuation Multiples (2)

P/B Ratio:0.38x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$6.95M

Price Action & Momentum (1)

% of 52-Week High:8.5%
B. Profitability Assessment

Return Metrics (5)

ROA:-82.7%
Reinvestment Rate:0.1%
Fundamental Growth Rate (g):-0.8%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$1.76K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:89.7%
Latest Earnings Filed:2026-08-06
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:6.21x
Quick Ratio:6.21x
Cash Ratio:6.11x

Leverage Analysis (3)

Debt To Equity Ttm:0.09x
Debt-to-Equity Ratio:0.09x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-110.41x
Times Interest Earned:-110.41

Capital Structure (4)

Working Capital:9,804,116.00
Cash And Cash Equivalents:11,482,792.00
Long Term Debt:$550.55K
Net Debt:-$10.74M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$11.27M

Bottom Line Performance (3)

-$10.75M
Income Before Tax:$0.00
Ebitda Ttm:-11,241,206.00

Operating Expenses (5)

Operating Expenses:11,269,339.00
R And D Expense:5,182,332.00
Sga Expense:6,087,007.00
Income Tax Expense:$0.00
Interest Expense:82,159.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$12.50M
Current Assets:$11.68M
Ppe Net:172,032.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:2,430,946.00
Current Liabilities:1,880,400.00
Long Term Debt:$550.55K
Short Term Debt:$189.37K

Equity & Capital (3)

Equity:$10.07M
Retained Earnings:-$55.75M
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:931,093.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:401,417.00
C. Cash Flow Analysis

Operating Activities (2)

-$8.69M-$8.29M

Investment Activities (1)

Investing Cash Flow:-$71.88K

Financing Activities (3)

Financing Cash Flow:$6.70M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:599,996.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:28,133.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-18.41
-$18.41
Earnings Per Share Ttm:-$2.81

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$2.16

Book Value & Capital (2)

Book Value Per Share:$2.63
Cash Per Share:3.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.1%
Fundamental Growth Rate (g):-0.8%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):15.8%
C. Company Profile & Context

Corporate Information (6)

Symbol:REVB
Company Name:REVELATION BIOSCIENCES, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:3.83M
Shares Outstanding Basic:3.83M
Shares Outstanding Diluted:3.83M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 19:42:14 UTC
Data Timestamp:2026-08-22T07:29:34.750717
Scroll to Top